|Bid||0.00 x 900|
|Ask||18.99 x 1000|
|Day's Range||17.78 - 19.07|
|52 Week Range||16.54 - 24.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HAMILTON, Bermuda, June 14, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the JMP Securities 2018 Life Sciences Conference on Thursday, June 21 st, 2018 at 10:30 a.m. ...
In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...
HAMILTON, Bermuda, May 29, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today the closing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share. ...
Kiniksa Pharmaceuticals, Ltd. (KNSA), a clinical-stage biopharmaceutical company, visited the Nasdaq MarketSite in Times Square today for its initial public offering (IPO) on The Nasdaq Stock Market. Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with unmet medical need. “As it works to develop life-changing therapies for debilitating diseases, Kiniksa Pharmaceuticals represents the kind of ambitious, forward-thinking growth company that embodies the Nasdaq spirit,” said Nelson Griggs, President, Nasdaq Stock Exchange.
HAMILTON, Bermuda, May 23, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, ...